This article first appeared on GuruFocus.
XLV led ETF activity in Eli Lilly (LLY) on Thursday, as funds bought a net $40.6 million of the stock. Thirty-eight ETFs were buying while 22 were selling. The move extended a four-day streak of net buying, following $36.3 million on Wednesday, $22.0 million on Tuesday and $62.0 million on Monday. The prior session, Oct. 23, had seen a net $23.2 million sold.
Track the latest ETF buying and selling trends and search funds in the GuruFocus ETF Screener.
For the full record of ETF and guru buying and selling in LLY, see the LLY guru trades page.
Which ETFs bought LLY on Thursday?
The largest buyers by dollar value were XLV ($69.8 million), IWF ($6.7 million) and AVUS ($1.6 million). In all, 38 ETFs added shares and 22 cut them.
XLV accounted for the largest share of the move, adding 50,830 shares worth $69.8 million, a 0.88% increase in its stake, with the position at 16.49% of the fund. IWF added 4,851 shares worth $6.7 million, while AVUS added 1,155 shares worth $1.6 million and HCMT added 1,101 shares worth $1.5 million. IHE, IUSG, AVLV and GPIX also added smaller amounts. Eli Lilly operates in the Healthcare sector, in the Drug Manufacturers – General industry, and carries a market cap of $1.33 trillion.
Have ETFs been buying or selling LLY lately?
Over the last 5 reported days, ETFs were net buyers on 4 and net sellers on 1, so the recent trend is mostly buying.
What does LLY do?
Eli Lilly discovers, develops, manufactures, and markets human pharmaceutical products in a single business segment, with medicines sold in approximately 90 countries. Its cardiometabolic health franchise leads the portfolio, anchored by the incretin medicines Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea, alongside Trulicity, Jardiance, and insulins.
Eli Lilly reported trailing-12-month revenue of $86.46 billion, up 46.3% over one year. Gross margin was 83.6% and net margin 31.9%. The stock trades at a P/E of 46.57, a P/B of 33.13 and a P/S of 14.84, with a market cap of $1.33 trillion. Its GF Score is 97, and GF Value of $1,590.33 compares with a price of $1,417.54. The dividend yield is 0.49%, and the stock has returned 32.54% year to date.